Abstract
Seven hundred and fifty nine patients with malignant tumors were treated by intra-arterial infusion with microencapsulated anticancer drugs from 1978 to 1986. Mean age of the patients was 60.3 yrs(13-88). Fifty seven percents of patients had stage 4 tumor and 41%were grade 3-4 in performans status. The target organs subjected to the treatment were liver(310), kidney(177), bladder(100), prostate(41), lung(39), pelvic organs(13), bone(4)and the others (75). Median doses of drugs in microcapsules were 20 mg for MMC, 40 mg for PEP and 60 mg for CDDP. Of 455 measurable tumors, 113(25%)showed a substantial reduction of greater than 50%. In 508 evaluable patients, side effects frequently recognized were fever(57%)and local pain(50%)shortly after the treatment. However, these side effects were generally mild and temporary. Gluteal skin ulcer occured in 33 patients(21%)who underwent hypogastric arterial infusion, but improved within a few months. Only one patient died of treatment-related cause. These results suggested that microcapsule therapy can be successfully applied to a variety of tumors with low morbidity and low mortality, and also can be combined with other treatments in multidisciplinary therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
